Monte Rosa Therapeutics reported preliminary cash and cash equivalents of $377 million as of December 31, 2024, including a $150 million payment from Novartis, but these figures are subject to change pending final accounting. The company also provided a corporate update and key milestones for 2025 during the J.P. Morgan Healthcare Conference.